Greenspring Advisors LLC Has $1.23 Million Position in Eli Lilly and Company (NYSE:LLY)

Greenspring Advisors LLC increased its position in Eli Lilly and Company (NYSE:LLY) by 20.2% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,490 shares of the company’s stock after buying an additional 250 shares during the period. Greenspring Advisors LLC’s holdings in Eli Lilly and Company were worth $1,231,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in LLY. FPC Investment Advisory Inc. grew its holdings in Eli Lilly and Company by 358.3% during the fourth quarter. FPC Investment Advisory Inc. now owns 55 shares of the company’s stock valued at $45,000 after purchasing an additional 43 shares during the last quarter. Mascagni Wealth Management Inc. acquired a new position in Eli Lilly and Company during the fourth quarter valued at approximately $43,000. Prudent Man Investment Management Inc. acquired a new position in Eli Lilly and Company during the fourth quarter valued at approximately $48,000. Compass Financial Services Inc acquired a new position in Eli Lilly and Company during the fourth quarter valued at approximately $50,000. Finally, Capital A Wealth Management LLC acquired a new position in Eli Lilly and Company during the fourth quarter valued at approximately $63,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have commented on LLY. UBS Group lowered their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a “buy” rating on the stock in a report on Friday, May 2nd. Erste Group Bank downgraded Eli Lilly and Company from a “buy” rating to a “hold” rating in a report on Thursday. Wall Street Zen upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Saturday. Hsbc Global Res cut Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a research report on Monday, April 28th. Finally, Wells Fargo & Company reissued an “overweight” rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eighteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus target price of $1,011.37.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,840 shares of the company’s stock, valued at approximately $4,778,521.60. This trade represents a 14.62% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Up 0.6%

Shares of LLY stock opened at $770.00 on Friday. The stock has a market cap of $729.76 billion, a P/E ratio of 65.76, a price-to-earnings-growth ratio of 1.40 and a beta of 0.40. Eli Lilly and Company has a one year low of $677.09 and a one year high of $972.53. The stock has a fifty day moving average price of $770.87 and a 200 day moving average price of $800.27. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). The firm had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The firm’s revenue for the quarter was up 45.2% compared to the same quarter last year. During the same period last year, the business earned $2.58 earnings per share. Analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be issued a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.78%. Eli Lilly and Company’s payout ratio is presently 48.82%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.